Compare Invesco S&P 500 Low Volatility ETF (SPLV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 Low Volatility ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Invesco S&P 500 Low Volatility ETF trades at $75.74, while State Street SPDR S&P Biotech ETF trades at $158.23. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Invesco S&P 500 Low Volatility ETF nearer its low. Which is the better fit depends on your goals.
| SPLV | XBI | |
|---|---|---|
52-Week High | $77.97 | $164.28 |
52-Week Low | $70.30 | $86.92 |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPLV trades at $76.21, down 0.07% with neutral technical signals. The ETF focuses on low-volatility S&P 500 stocks, offering stability amid market uncertainty. Recent news highlights its role in diversification as investors seek shelter from tech sell-offs and geopolitical tensions. Moving averages show a bullish trend, while oscillators indicate neutrality, with RSI at 55.45 suggesting balanced momentum.
Outlook: SPLV provides defensive exposure with historical resilience, but reliance on low-volatility factors may lag in bullish markets. Risks include concentrated sector bets and interest rate sensitivity. Analyst sentiment is mixed, reflecting its niche role in risk-averse portfolios.
XBI, the SPDR S&P Biotech ETF, trades at $157.37, up 1.88% today, with a bullish technical signal from moving averages and strong momentum indicators. The ETF has surged nearly 17% in a month, driven by positive clinical trial news and increased M&A activity in the biotech sector. Analyst coverage is limited to one hold rating, reflecting cautious optimism amid high volatility.
Outlook remains positive due to sector tailwinds like AI-driven drug discovery and robust M&A, but risks include policy uncertainty and the fund's high beta. Investors should weigh the potential for continued growth against inherent volatility in small- and mid-cap biotech holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
